Altasciences has appointed Dr. Wendell P. Davis, D.V.M., Dipl. ACVP, as Vice President, Pathology. Dr. Davis is a nonclinical development professional with extensive experience in toxicologic pathology and a track record of building and leading high functioning pathology groups in both the biotechnology and CRO sectors. 
 

As a study pathologist and peer reviewer, he has experience evaluating small molecules, biologics, oligonucleotide, and an array of RNA therapeutics modalities across a range of preclinical species and routes of administration, in support of both early candidate selection and regulatory filings. 
 
“Wendell’s track record and leadership experience in the fields of anatomical pathology, discovery toxicology, and toxicologic pathology, as well as his ability to mitigate challenging toxicologic pathology issues will make him a great addition to our team, and deliver expert guidance for our clients,” said Mike Broadhurst, General Manager, Preclinical Services, at Altasciences. 
 
Altasciences has preclinical research facilities in Seattle, Scranton, and Columbia, U.S. The company offers a full range of in vivo GLP and non-GLP preclinical studies in multiple species to thoroughly assess the safety profile of molecules.